ASH 2023 | ELM-2: promising safety and efficacy of odronextamab in R/R DLBCL
Sabarish Ayyappan, MD, City of Hope, Atlanta, GA, presents results from the ELM-2 study (NCT03888105), investigating the safety and efficacy of odronextamab, a CD20xCD3 bispecific antibody, in the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The results indicate a 51% overall response rate (ORR) and a 32% complete response (CR), with low-grade adverse events (AEs), including cytokine release syndrome (CRS), which was managed with a step-up administration regimen. Measurable residual disease (MRD) and circulating tumor DNA (ctDNA) levels served as predictive factors for progression-free survival (PFS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: TG Therapeutics, Intellisphere, AstraZeneca, ADC Therapeutics; Membership on an entity’s Board of Directors or advisory committees: TG Therapeutics, Intellisphere, AstraZeneca, ADC Therapeutics, Seattle Genetics, Fate Therapeutics, Beigene, AbbVie; Speakers Bureau: Total CME.
